PD-L1 Mediates IFNγ-Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma

被引:8
|
作者
Garige, Mamatha [1 ]
Ghosh, Susmita [1 ]
Norris, Alexis [2 ]
Li, Guangyuan [1 ]
Poncet, Sarah [1 ]
Chou, Chao-Kai [3 ]
Wu, Wells W. [3 ]
Shen, Rong-Fong [3 ]
Sourbier, Carole [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Div Biotechnol Review & Res 1, Off Biotechnol Prod,Off Pharmaceut Qual, Silver Spring, MD 20993 USA
[2] US FDA, Ctr Vet Med, Div Anim Bioengn & Cellular Therapies, Off New Anim Drug Evaluat, Rockville, MD USA
[3] US FDA, Ctr Biol Evaluat & Res, Facil Biotechnol Resources, Drug Adm, Silver Spring, MD USA
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
PD-L1 (B7-H1; CD274); clear cell renal cell carcinoma (ccRCC); interferon gamma; metabolism; tryptophan; kynurenine; glycolysis; INDOLEAMINE 2,3-DIOXYGENASE; SUPPRESSOR-CELLS; INTERFERON-GAMMA; T-CELLS; CANCER; MICROENVIRONMENT; INFLAMMATION; EXPRESSION; LINDAU; ACID;
D O I
10.3389/fonc.2022.858379
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The immune checkpoint programmed death-ligand 1 (PD-L1) is expressed on the cell surface of tumor cells and is key for maintaining an immunosuppressive microenvironment through its interaction with the programmed death 1 (PD-1). Clear cell renal cell carcinoma (ccRCC) is a highly immunogenic cancer characterized by an aberrant aerobic glycolytic metabolism and is known to overexpress PD-L1. Multiple immunotherapies have been approved for the treatment of ccRCC, including cytokines and immune checkpoint inhibitors. Recently the intrinsic role of PD-L1 and interferon gamma (IFN gamma) signaling have been studied in several types of tumor cells, yet it remains unclear how they affect the metabolism and signaling pathways of ccRCC. Using metabolomics, metabolic assays and RNAseq, we showed that IFN gamma enhanced aerobic glycolysis and tryptophan metabolism in ccRCC cells in vitro and induced the transcriptional expression of signaling pathways related to inflammation, cell proliferation and cellular energetics. These metabolic and transcriptional effects were partially reversed following transient PD-L1 silencing. Aerobic glycolysis, as well as signaling pathways related to inflammation, were not induced by IFN gamma when PD-L1 was silenced, however, tryptophan metabolism and activation of Jak2 and STAT1 were maintained. Our data demonstrate that PD-L1 expression is required to mediate some of IFN gamma's effect in ccRCC cells and highlight the importance of PD-L1 signaling in regulating the metabolism of ccRCC cells in response to inflammatory signals.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] PD1/PD-L1 therapy in metastatic renal cell carcinoma
    Bruchbacher, Andreas
    Lemberger, Ursula
    Hassler, Melanie R.
    Fajkovic, Harun
    Schmidinger, Manuela
    CURRENT OPINION IN UROLOGY, 2020, 30 (04) : 534 - 541
  • [42] Comparing the performance of three PD-L1 antibodies for PD-L1 expression in renal cell carcinoma
    Park, S.
    Wi, Y. C.
    Shin, S.
    Jang, K.
    VIRCHOWS ARCHIV, 2019, 475 : S181 - S182
  • [43] Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma
    Ge, Wenfei
    Song, Shiyan
    Qi, Xiaochen
    Chen, Feng
    Che, Xiangyu
    Sun, Yonghao
    Wang, Jin
    Li, Xiaowei
    Liu, Nana
    Wang, Qifei
    Wu, Guangzhen
    ONCOLOGY RESEARCH, 2023, 31 (03) : 255 - 270
  • [44] PD-L1 Expression By Immunohistochemistry in Clear Cell Renal Cell Carcinoma Is Associated With High Tumor Stage and Nuclear Grade
    Goodman, Steven
    Tanzboli, Pheroze
    Rodriguez-Canales, Jaime
    Parra, Edwin
    Karam, Jose
    Wood, Christopher
    Rao, Priya
    MODERN PATHOLOGY, 2015, 28 : 223A - 224A
  • [45] PD-L1 expression in different non-clear cell renal cell carcinoma subtypes: an analysis of the SUNNIFORECAST cohort
    Ahrens, M.
    Vorfelder, L.
    Stoehr, C.
    Haanen, J.
    Escudier, B.
    Goupil, Gross M.
    Boleti, E.
    Gravis, G.
    Grimm, M. -O
    Negrier, S.
    Bedtke, J.
    Barthelemy, P.
    Castellano, D.
    Mellado, B.
    Ivanyi, P.
    Rottey, S.
    Floercken, A.
    Maroto, J. P.
    Suarez Rodriguez, C.
    Oosting, S.
    Panic, A.
    Hartmann, A.
    Bergmann, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 77 - 78
  • [46] Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy
    Lopez, Jose, I
    Pulido, Rafael
    Cortes, Jesus M.
    Angulo, Javier C.
    Lawrie, Charles H.
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (08) : 1110 - 1114
  • [47] Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma
    Chrabanska, Magdalena
    Szweda-Gandor, Nikola
    Rynkiewicz, Magdalena
    Hrabos, Dominik
    Drozdzowska, Bogna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (07)
  • [48] PD-L1 Expression By Immunohistochemistry in Clear Cell Renal Cell Carcinoma Is Associated With High Tumor Stage and Nuclear Grade
    Goodman, Steven
    Tamboli, Pheroze
    Rodriguez-Canales, Jaime
    Parra, Edwin
    Karam, Jose
    Wood, Christopher
    Rao, Priya
    LABORATORY INVESTIGATION, 2015, 95 : 223A - 224A
  • [49] PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI-Resistant Metastatic Clear Cell Renal Cell Carcinoma
    Jeong, Se Un
    Hwang, Hee Sang
    Park, Ja-Min
    Yoon, Sun Young
    Shin, Su-Jin
    Go, Heounjeong
    Lee, Jae-Lyun
    Jeong, Gowun
    Cho, Yong Mee
    CANCER RESEARCH AND TREATMENT, 2023, 55 (01): : 231 - 244
  • [50] Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma
    Eckel-Passow, Jeanette E.
    Ho, Thai H.
    Serie, Daniel J.
    Cheville, John C.
    Thompson, R. Houston
    Costello, Brian A.
    Dong, Haidong
    Kwon, Eugene D.
    Leibovich, Bradley C.
    Parker, Alexander S.
    CANCER MEDICINE, 2020, 9 (03): : 1152 - 1160